Amgen and Genentech Sign License Agreements For Antibody Patents
THOUSAND OAKS, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS
WIRE)--Jan. 26, 2006--Amgen (NASDAQ:AMGN) and Genentech Inc.
(NYSE:DNA) today announced that they have entered into license
agreements granting licenses to each other under multiple patents
relating to the manufacture and use of antibodies and related
technology. These agreements include a grant by Genentech to Amgen of
a license for multiple antibodies under the Cabilly patent family
(U.S. Patent No. 6,331,415 et al.) relating in part to methods of
Financial details of the license agreements were not disclosed.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
Genentech is a leading biotechnology company that discovers,
develops, manufactures, and commercializes biotherapeutics for
significant unmet medical needs. A considerable number of the
currently approved biotechnology products originated from or are based
on Genentech science. Genentech manufactures and commercializes
multiple biotechnology products and licenses several additional
products to other companies. The company has headquarters in South San
Francisco, Calif., and is listed on the New York Stock Exchange under
the symbol DNA. For additional information about the company, please
Kristen Klasey (Media), 805-447-4587
Arvind Sood (Investor Relations), 805-447-1060
Caroline Pecquet (Media), 650-467-7078
Kathee Littrell (Investor Relations), 650-225-1034